cyclophosphamide
cyclophosphamide is listed in the FDA National Drug Code directory with 48 NDC codes, marketed under brand names including Cyclophosphamide, CYCLOPHOSPHAMIDE. Available dosage forms: injection, powder, for solution, injection, solution, powder.
Drug details
- Generic Name
- cyclophosphamide
- Brand Names
- Cyclophosphamide, CYCLOPHOSPHAMIDE
- Application Number
- ANDA218644
- Sponsor
- Epic Pharma, LLC
- NDC Codes
- 48
- Dosage Forms
- INJECTION, POWDER, FOR SOLUTION, INJECTION, SOLUTION, POWDER
- Routes
- INTRAVENOUS, ORAL
- Active Ingredients
- CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE ANHYDROUS
Indications and Usage
1 INDICATIONS AND USAGE Cyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1.1 ) 1.1 Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.